← FDA DRUG APPROVALS

FDA ANDA · ANDA204319

OLANZAPINE

Sponsor: QILU

APPLICATION
ANDA204319
TYPE
ANDA
ORIGINAL APPROVAL
2016-01-27
LATEST ACTION
2021-11-18
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

OLANZAPINEPrescription
OLANZAPINE 20MG · TABLET · ORAL
OLANZAPINEPrescription
OLANZAPINE 10MG · TABLET · ORAL
OLANZAPINEPrescription
OLANZAPINE 5MG · TABLET · ORAL
OLANZAPINEPrescription
OLANZAPINE 15MG · TABLET · ORAL
OLANZAPINEPrescription
OLANZAPINE 7.5MG · TABLET · ORAL
OLANZAPINEPrescription
OLANZAPINE 2.5MG · TABLET · ORAL

Approval history

2021-11-18Labeling · Supplement 8 · standardAP
2021-11-18Labeling · Supplement 7 · standardAP
2021-11-18Labeling · Supplement 3 · standardAP
2021-11-18Labeling · Supplement 1 · standardAP
2016-01-27UNKNOWN · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →